Authors : Afnan Ahmed Khan; Israt Jerin Tonni; Md. Shohel Al Faruk; Shormin Akter

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/4kme3fj3

DOI : https://doi.org/10.38124/ijisrt/25jul144

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Leptospirosis, an emerging global zoonotic disease caused by Leptospira species. A wide range of clinical symptoms are present in this condition, from a low-grade fever to potentially fatal side effects like Weil's disease and pulmonary hemorrhage syndrome. The pathophysiology remains incompletely understood despite being a disease of epidemic proportions, particularly in tropical regions. Recent developments have indicated the gut microbiota to be a potent modifier of systemic immunity and its potential to modulate disease severity in infectious diseases. The review discusses how the gut microbiota modulates the pathogenesis of leptospirosis through dysbiosis, leading to immune dysregulation and systemic inflammation while causing localized damage to specific organs. Related bacterial infection research indicates that disruptions in gut microbiota worsen immune system imbalances and cytokine storms while intensifying multi-organ failure in severe leptospirosis cases. Microbiota-directed therapeutic approaches including probiotics, prebiotics, fecal microbiota transplantation and dietary modifications may decrease disease severity and improve clinical outcomes. There are several knowledge gaps in leptospirosis research that require comprehensive microbiota profiles, mechanisms of action and clinical trials to address and evaluate these therapeutic approaches. This review emphasizes that combining microbiota approaches with leptospirosis research will provide a novel, and potentially fruitful, direction for therapeutic development and address the acute need for new therapeutic against the neglected tropical disease.

References :

1. Al-orry, Waleed, et al. "Leptospirosis: transmission, diagnosis and prevention." International Journal of Innovation and Applied Studies 15.3 (2016): 457.
2. Haake, David A., and Paul N. Levett. "Leptospirosis in humans." Leptospira and leptospirosis (2015): 65-97.
3. Feigin, Ralph D., Donald C. Anderson, and Clark W. Heath. "Human leptospirosis." Crc critical reviews in clinical laboratory sciences 5.4 (1975): 413-467.
4. Terpstra, W. J. Human leptospirosis: guidance for diagnosis, surveillance and control. World Health Organization, 2003.
5. Petakh, Pavlo, et al. "Exploring the complex interplay: gut microbiome, stress, and leptospirosis." Frontiers in Microbiology 15 (2024): 1345684.
6. Chancharoenthana, Wiwat, et al. "Going micro in leptospirosis kidney disease." Cells 11.4 (2022): 698.
7. Wiertsema, Selma P., et al. "The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies." Nutrients 13.3 (2021): 886.
8. Gomaa, Eman Zakaria. "Human gut microbiota/microbiome in health and diseases: a review." Antonie Van Leeuwenhoek 113.12 (2020): 2019-2040.
9. Brüssow, Harald. "Problems with the concept of gut microbiota dysbiosis." Microbial biotechnology 13.2 (2020): 423-434.
10. DuPont, Andrew W., and Herbert L. DuPont. "The intestinal microbiota and chronic disorders of the gut." Nature reviews Gastroenterology & hepatology 8.9 (2011): 523-531.
11. Dhar, Debojyoti, and Abhishek Mohanty. "Gut microbiota and Covid-19-possible link and implications." Virus research 285 (2020): 198018.
12. Schuijt, Tim J., et al. "The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia." Gut 65.4 (2016): 575-583.
13. Cristofori, Fernanda, et al. "Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body." Frontiers in immunology 12 (2021): 578386.
14. Wu, Zeguang, et al. "Acute liver failure: mechanisms of immune‐mediated liver injury." Liver International 30.6 (2010): 782-794.
15. Chancharoenthana, Wiwat, et al. "The leaky gut and the gut microbiome in sepsis–targets in research and treatment." Clinical Science 137.8 (2023): 645-662.
16. Xie, Xufeng, et al. "Gut microbiota involved in leptospiral infections." The ISME Journal 16.3 (2022): 764-773.
17. Helmerhorst, H. J., et al. "Severe pulmonary manifestation of leptospirosis." Neth J Med 70.5 (2012): 215-21.
18. Felix, Carolina R., et al. "An overview of human leptospirosis vaccine design and future perspectives." Expert opinion on drug discovery 15.2 (2020): 179-188.
19. Limothai, Umaporn, et al. "The role of leptospiremia and specific immune response in severe leptospirosis." Scientific Reports 11.1 (2021): 14630.
20. Evangelista, Karen V., and Jenifer Coburn. "Leptospira as an emerging pathogen: a review of its biology, pathogenesis and host immune responses." Future microbiology 5.9 (2010): 1413-1425.
21. De Brito, Thales, Ana Maria Gonçalves da Silva, and Patrícia Antonia Estima Abreu. "Pathology and pathogenesis of human leptospirosis: a commented review." Revista do Instituto de Medicina Tropical de São Paulo 60 (2018): e23.
22. Faisal, Syed M., Sean P. McDonough, and Yung-Fu Chang. "Leptospira: Invasion, pathogenesis and persistence." The pathogenic spirochetes: Strategies for evasion of host immunity and persistence (2012): 143-172.
23. Birtles, Richard. "Leptospira infections." Infectious diseases of wild mammals and birds in Europe (2012): 402-408.
24. Shetty, Advait Bhaskar. Host-Pathogen Interactions During Leptospirosis in Male C3H/HeJ Mice. The University of Tennessee Health Science Center, 2022.
25. Fraga, Tatiana Rodrigues, Angela Silva Barbosa, and Lourdes Isaac. "Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system." Scandinavian journal of immunology 73.5 (2011): 408-419.
26. Hota, Saswat, Md Saddam Hussain, and Manish Kumar. "ErpY-like lipoprotein of Leptospira outsmarts host complement regulation by acquiring complement regulators, activating alternative pathways, and intervening in the membrane attack complex." ACS Infectious Diseases 8.5 (2022): 982-997.
27. Barbosa, Angela S., et al. "Immune evasion of leptospira species by acquisition of human complement regulator C4BP." Infection and immunity 77.3 (2009): 1137-1143.
28. Atzingen, Marina V., et al. "Lsa21, a novel leptospiral protein binding adhesive matrix molecules and present during human infection." BMC microbiology 8 (2008): 1-16.
29. Domingos, Renan F., et al. "Features of two proteins of Leptospira interrogans with potential role in host-pathogen interactions." BMC microbiology 12 (2012): 1-16.
30. Robbins, Gregory T., et al. "Evaluation of cell binding activities of Leptospira ECM adhesins." PLoS neglected tropical diseases 9.4 (2015): e0003712.
31. Santecchia, Ignacio, et al. "Phagocyte escape of Leptospira: the role of TLRs and NLRs." Frontiers in immunology 11 (2020): 571816.
32. Cagliero, Julie, Sharon YAM Villanueva, and Mariko Matsui. "Leptospirosis pathophysiology: into the storm of cytokines." Frontiers in cellular and infection microbiology 8 (2018): 204.
33. Sun, Ai-Hua, Xiao-Xiang Liu, and Jie Yan. "Leptospirosis is an invasive infectious and systemic inflammatory disease." Biomedical journal 43.1 (2020): 24-31.
34. Fraga, Tatiana Rodrigues, Angela Silva Barbosa, and Lourdes Isaac. "Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system." Scandinavian journal of immunology 73.5 (2011): 408-419.
35. Senavirathna, Indika, Devarajan Rathish, and Suneth Agampodi. "Cytokine response in human leptospirosis with different clinical outcomes: a systematic review." BMC Infectious Diseases 20 (2020): 1-8.
36. Marshall, R. B. "The route of entry of leptospires into the kidney tubule." Journal of Medical Microbiology 9.2 (1976): 149-152.
37. Ondee, Thunnicha, et al. "Lipocalin-2 (Lcn-2) attenuates polymicrobial sepsis with LPS preconditioning (LPS tolerance) in FcGRIIb deficient lupus mice." Cells 8.9 (2019): 1064.
38. Gnauck, Anne, Roger G. Lentle, and Marlena C. Kruger. "The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans." International reviews of immunology 35.3 (2016): 189-218.
39. Yang, Chih-Wei, et al. "Leptospira outer membrane protein activates NF-κB and downstream genes expressed in medullary thick ascending limb cells." Journal of the American Society of Nephrology 11.11 (2000): 2017-2026.
40. Haake, David A. "Leptospiral major outer membrane protein LipL32." U.S. Patent No. 6,306,623. 23 Oct. 2001.
41. Taylor, Andrew J., Daniel H. Paris, and Paul N. Newton. "A systematic review of the mortality from untreated leptospirosis." PLoS neglected tropical diseases 9.6 (2015): e0003866.
42. Gancheva, Galya Ivanova. "Liver involvement in leptospirosis." population 2006 (2009): 8.
43. De Brito, Thales, Ana Maria Gonçalves da Silva, and Patrícia Antonia Estima Abreu. "Pathology and pathogenesis of human leptospirosis: a commented review." Revista do Instituto de Medicina Tropical de São Paulo 60 (2018): e23.
44. De Brito, T., et al. "Liver biopsy in human leptospirosis: a light and electron microscopy study." Virchows Archiv fur pathologische Anatomie und Physiologie und fur klinische Medizin 342.1 (1967): 61-69.
45. Alves, Venâncio Avancini Ferreira, et al. "Leptospiral antigens in the liver of experimentally infected guinea pig and their relation to the morphogenesis of liver damage." Experimental and Toxicologic Pathology 44.7 (1992): 425-434.

46. De Brito, T., et al. "Pathology of the kidney and liver in the experimental leptospirosis of the guinea-pig. A light and electron microscopy study." Virchows Archiv fur Pathologische Anatomie und Physiologie und fur Klinische Medizin 341.1 (1966): 64-78.
47. Haake, David A. "Hamster model of leptospirosis." Current protocols in microbiology 2.1 (2006): 12E-2.

48. Miyahara, Satoshi, et al. "Destruction of the hepatocyte junction by intercellular invasion of L eptospira causes jaundice in a hamster model of Weil's disease." International journal of experimental pathology 95.4 (2014): 271-281.
49. Segura, Eddy R., et al. "Clinical spectrum of pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral burden." Clinical infectious diseases 40.3 (2005): 343-351.
50. Gouveia, Edilane L., et al. "Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil." Emerging infectious diseases 14.3 (2008): 505.
51. Miller, Norman G., Judith E. Allen, and Richard B. Wilson. "The pathogenesis of hemorrhage in the lung of the hamster during acute leptospirosis." Medical Microbiology and Immunology 160.4 (1974): 269-278.
52. Ren, Shuang-Xi, et al. "Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing." Nature 422.6934 (2003): 888-893.
53. Bulach, Dieter M., et al. "Genome reduction in Leptospira borgpetersenii reflects limited transmission potential." Proceedings of the National Academy of Sciences 103.39 (2006): 14560-14565.
54. Nally, Jarlath E., et al. "Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis." The American journal of pathology 164.3 (2004): 1115-1127.
55. Seguro, Antonio Carlos, and Lucia Andrade. "Pathophysiology of leptospirosis." Shock 39 (2013): 17-23.
56. Andrade, Lúcia, et al. "Leptospirosis leads to dysregulation of sodium transporters in the kidney and lung." American Journal of Physiology-Renal Physiology 292.2 (2007): F586-F592.
57. Maciel-Fiuza, Miriãn Ferrão, et al. "Role of gut microbiota in infectious and inflammatory diseases." Frontiers in microbiology 14 (2023): 1098386.
58. Fang, Zhifeng, et al. "Gut microbiota, probiotics, and their interactions in prevention and treatment of atopic dermatitis: a review." Frontiers in immunology 12 (2021): 720393.
59. Kosiewicz, Michele M., Arin L. Zirnheld, and Pascale Alard. "Gut microbiota, immunity, and disease: a complex relationship." Frontiers in microbiology 2 (2011):
60. Wang, Chenyang, Qiurong Li, and Jianan Ren. "Microbiota-immune interaction in the pathogenesis of gut-derived infection." Frontiers in immunology 10 (2019): 1873.
61. Galán, Jorge E. "Salmonella Typhimurium and inflammation: a pathogen-centric affair." Nature Reviews Microbiology 19.11 (2021): 716-725.
62.  McDonald, Daniel, et al. "Extreme dysbiosis of the microbiome in critical illness." Msphere 1.4 (2016): 10-1128.
63. Campbell, Connor, et al. "Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy." Biomedicines 11.2 (2023): 294.
64. Geem, Duke, et al. "Harnessing regulatory T cells for the treatment of inflammatory bowel disease." Inflammatory bowel diseases 21.6 (2015): 1409-1418.
65. Arredondo-Hernandez, Rene, et al. "Clostridium difficile infection: an immunological conundrum." Archives of Medical Research 49.6 (2018): 359-364.
66. Sencio, Valentin, Marina Gomes Machado, and Francois Trottein. "The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes." Mucosal Immunology 14.2 (2021): 296-304.
67. Petersen, Charisse, and June L. Round. "Defining dysbiosis and its influence on host immunity and disease." Cellular microbiology 16.7 (2014): 1024-1033.
68. Schuijt, Tim J., et al. "The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia." Gut 65.4 (2016): 575-583.
69. Zhang, Yingying, et al. "Dysbiosis of gut microbiota and intestinal barrier dysfunction in pigs with pulmonary inflammation induced by mycoplasma hyorhinis infection." Msystems 7.4 (2022): e00282-22.
70. Tang, Yuxiu, et al. "Gut microbes improve prognosis of Klebsiella pneumoniae pulmonary infection through the lung-gut axis." Frontiers in Cellular and Infection Microbiology 14 (2024): 1392376.
71. Shukla, Shakti D., et al. "Microbiome effects on immunity, health and disease in the lung." Clinical & translational immunology 6.3 (2017): e133.
72. Fang, Zhifeng, et al. "Gut microbiota, probiotics, and their interactions in prevention and treatment of atopic dermatitis: a review." Frontiers in immunology 12 (2021): 720393.
73. Petakh, Pavlo, et al. "Weil’s Disease—Immunopathogenesis, Multiple Organ Failure, and Potential Role of Gut Microbiota." Biomolecules 12.12 (2022): 1830.
74. Wang, Gang, et al. "Bridging intestinal immunity and gut microbiota by metabolites." Cellular and Molecular Life Sciences 76 (2019): 3917-3937.
75. Rutsch, Andrina, Johan B. Kantsjö, and Francesca Ronchi. "The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology." Frontiers in immunology 11 (2020): 604179.
76. Martínez-López, María, et al. "Leishmania hijacks myeloid cells for immune escape." Frontiers in microbiology 9 (2018): 883.

77. Chang, Pamela V., et al. "The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition." Proceedings of the National Academy of Sciences 111.6 (2014): 2247-2252.
78. Wang, Yanchun, et al. "Scavenger receptor A1 participates in uptake of Leptospira interrogans serovar Autumnalis strain 56606v and inflammation in mouse macrophages." Emerging Microbes & Infections 10.1 (2021): 939-953.

79. Voss, Oliver H., et al. "Lipopolysaccharide-induced CD300b receptor binding to toll-like receptor 4 alters signaling to drive cytokine responses that enhance septic shock." Immunity 44.6 (2016): 1365-1378.
80. Lehman, Heather K., and Brahm H. Segal. "The role of neutrophils in host defense and disease." Journal of Allergy and Clinical Immunology 145.6 (2020): 1535-1544.
81. Duarte-Neto, Amaro Nunes, et al. "Severe leptospirosis features in the spleen indicate cellular immunosuppression similar to that found in septic shock." Frontiers in immunology 10 (2019): 920.
82. Santecchia, Ignacio, et al. "Phagocyte escape of Leptospira: the role of TLRs and NLRs." Frontiers in immunology 11 (2020): 571816.
83. Petakh, Pavlo, et al. "Weil’s Disease—Immunopathogenesis, Multiple Organ Failure, and Potential Role of Gut Microbiota." Biomolecules 12.12 (2022): 1830.
84. Kosiewicz, Michele M., Arin L. Zirnheld, and Pascale Alard. "Gut microbiota, immunity, and disease: a complex relationship." Frontiers in microbiology 2 (2011): 180.
85. Raffray, Loic, et al. "High leptospiremia is associated with low gamma–delta T cell counts." Microbes and Infection 17.6 (2015): 451-455.
86. Petakh, Pavlo, and Vitaliia Isevych. "Gut microbiota status in leptospirosis: An unrecognized player?." New Microbes and New Infections 49 (2022): 101038.
87. Lei, Hong, et al. "Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners." Frontiers in pharmacology 6 (2015): 184.
88. Omenetti, Sara, and Theresa T. Pizarro. "The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome." Frontiers in immunology 6 (2015): 639.
89. Sadagopan, Aishwarya, et al. "Understanding the role of the gut microbiome in diabetes and therapeutics targeting leaky gut: a systematic review." Cureus 15.7 (2023).
90. Cagliero, Julie, Sharon YAM Villanueva, and Mariko Matsui. "Leptospirosis pathophysiology: into the storm of cytokines." Frontiers in cellular and infection microbiology 8 (2018): 204.
91. Chancharoenthana, Wiwat, et al. "The leaky gut and the gut microbiome in sepsis–targets in research and treatment." Clinical Science 137.8 (2023): 645-662.

92. Fernando, Narmada, et al. "Effect of antimicrobial agents on inflammatory cytokines in acute leptospirosis." Antimicrobial Agents and Chemotherapy 62.5 (2018): 10-1128.
93. Duarte-Neto, Amaro Nunes, et al. "Severe leptospirosis features in the spleen indicate cellular immunosuppression similar to that found in septic shock." Frontiers in immunology 10 (2019): 920.
94. Bandara, Kanchana, et al. "Do the Th17 cells play a role in the pathogenesis of leptospirosis?." Canadian Journal of Infectious Diseases and Medical Microbiology 2018.1 (2018): 9704532.
95. Yoo, Ji Youn, et al. "Gut microbiota and immune system interactions." Microorganisms 8.10 (2020): 1587.
96. Pérez-Reytor, Diliana, et al. "Use of short-chain fatty acids for the recovery of the intestinal epithelial barrier affected by bacterial toxins." Frontiers in physiology 12 (2021): 650313.
97. Corrêa‐Oliveira, Renan, et al. "Regulation of immune cell function by short‐chain fatty acids." Clinical & translational immunology 5.4 (2016): e73.
98. Stenman, Lotta K., et al. "Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—randomized controlled trial." EBioMedicine 13 (2016): 190-200.
99. Carding, Simon, et al. "Dysbiosis of the gut microbiota in disease." Microbial ecology in health and disease 26.1 (2015): 26191.
100. Rajapakse, Senaka. "Leptospirosis: clinical aspects." Clinical Medicine 22.1 (2022): 14-17.
101. Yu, Zihan, et al. "The role of potential probiotic strains Lactobacillus reuteri in various intestinal diseases: New roles for an old player." Frontiers in Microbiology 14 (2023): 1095555.
102. Schäfer, T. V., et al. "Gut Barrier in Critical States of the Body." Biology Bulletin Reviews 12.4 (2022): 392-405.
103. Wang, Chenyang, Qiurong Li, and Jianan Ren. "Microbiota-immune interaction in the pathogenesis of gut-derived infection." Frontiers in immunology 10 (2019): 1873.
104. Raheem, Abdul, et al. "Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation." Frontiers in immunology 12 (2021): 616713.
105. Yin, Jiangtao, et al. "Lacticaseibacillus rhamnosus TR08 alleviated intestinal injury and modulated microbiota dysbiosis in septic mice." BMC microbiology 21 (2021): 1-10.
106. Petakh, Pavlo, et al. "Current treatment options for leptospirosis: a mini-review." Frontiers in microbiology 15 (2024): 1403765.
107. Guarino, Michele Pier Luca, et al. "Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults." Nutrients 12.4 (2020): 1037.
108. Zaiatz-Bittencourt, Vanessa, et al. "Butyrate limits human natural killer cell effector function." Scientific Reports 13.1 (2023): 2715.
109. Nawaz, Asad, et al. "The functionality of prebiotics as immunostimulant: Evidences from trials on terrestrial and aquatic animals." Fish & shellfish immunology 76 (2018): 272-278.
110. Halkjær, Sofie Ingdam, et al. "Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis." World Journal of Gastroenterology 29.20 (2023): 3185.
111. Malikowski, Thomas, Sahil Khanna, and Darrell S. Pardi. "Fecal microbiota transplantation for gastrointestinal disorders." Current opinion in gastroenterology 33.1 (2017): 8-13.
112. Rodrigues, Tania, et al. "Procedures in fecal microbiota transplantation for treating irritable bowel syndrome: systematic review and meta-analysis." Journal of Clinical Medicine 12.5 (2023): 1725.
113. Shao, Tihong, et al. "The evolving landscape of fecal microbial transplantation." Clinical reviews in allergy & immunology 65.2 (2023): 101-120.
114. Huwiler, Valentina V., et al. "The role of dietary fibre in enteral nutrition in Sepsis prevention and therapy: a narrative review." Nutrients 15.11 (2023): 2489.
115. Wang, Jiaqi, et al. "The preventable efficacy of β-glucan against leptospirosis." PLoS neglected tropical diseases 13.11 (2019): e0007789.